A preliminary dose-ranging trial of proglumide for the treatment of refractory schizophrenics. Academic Article uri icon

abstract

  • A dose-finding study of proglumide added to neuroleptics for the treatment of schizophrenic patients who were relatively refractory to their ongoing neuroleptic regimen was performed. Initially, four patients were open-label treated using a regimen of progressively increasing doses (proglumide 0.5-1024 mg/day) for 4 weeks. Afterwards, seven patients were given low doses (0.5 mg/day) followed by higher doses (500 mg/day) for a total period of 8 weeks. Overall, no improvement was seen in these refractory patients as a group at any dose. In individual patients, modest improvement or worsening of psychotic symptoms was observed. The results suggest that more potent cholecystokinin (CCK) antagonists and a greater knowledge of CCK pharmacology are needed before novel treatments exploiting the interaction of CCK and dopamine in the brain can be developed.

published proceedings

  • J Clin Psychopharmacol

altmetric score

  • 3

author list (cited authors)

  • Hicks, P. B., Vinogradov, S., Riney, S. J., Su, K., & Csernansky, J. G.

citation count

  • 4

complete list of authors

  • Hicks, PB||Vinogradov, S||Riney, SJ||Su, K||Csernansky, JG

publication date

  • June 1989